{"id":"anti-cd25-rhmab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Immunosuppression-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CD25 is highly expressed on activated T lymphocytes and regulatory T cells. By targeting CD25, this antibody prevents IL-2-mediated T cell expansion and can modulate immune responses. This mechanism is used therapeutically in autoimmune and inflammatory conditions where T cell activation drives pathology, and has also been explored in transplantation to prevent rejection.","oneSentence":"This recombinant humanized monoclonal antibody binds to CD25 (IL-2 receptor alpha chain) on activated T cells, blocking interleukin-2 signaling and suppressing T cell proliferation and activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:17:07.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune and inflammatory disorders (specific approved indications not definitively documented in public sources)"}]},"trialDetails":[{"nctId":"NCT06880419","phase":"PHASE2","title":"Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Acute Graft-versus-Host Disease","enrollment":174},{"nctId":"NCT06364319","phase":"PHASE4","title":"Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-04-15","conditions":"cGVHD","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"anti-CD25 rhMAb","genericName":"anti-CD25 rhMAb","companyName":"Peking University People's Hospital","companyId":"peking-university-people-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This recombinant humanized monoclonal antibody binds to CD25 (IL-2 receptor alpha chain) on activated T cells, blocking interleukin-2 signaling and suppressing T cell proliferation and activation. Used for Autoimmune and inflammatory disorders (specific approved indications not definitively documented in public sources).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}